DEATH AFTER SALVARSAN

نویسندگان

چکیده

منابع مشابه

Salvarsan Poisoning

a spectacular nature as to impress one with its specificity, but in very few cases indeed could such a belief be continued for any length of time. I have noticed that in the majority of cases, either repeated and refractory recurrences have followed, dashing to the ground the fervent hopes of the most optimistic experimenter, or such disastrous consequences have resulted which might well make t...

متن کامل

After Venus, mercury: syphilis treatment in the UK before Salvarsan.

At the beginning of the twentieth century, the treatment of syphilis varied substantially in the UK. Two of the commonly used treatments—mercury and bismuth— were often used for long durations, which prompted the public health warning, ‘two minutes with Venus, two years with mercury’. Beyond this variation in treatment, venereology itself was a topic taught to generalists rather than specialist...

متن کامل

Close - to - Death Experience after Trauma

تجربه نزدیک به مرگ، یکسری وقایع واضحی است که توسط افراد معدودی بعد از دوره ای از مرگ بالینی گزارش می گردد (بعضی از افراد این تجربیات را به دنبال جراحی، تولد بچه و خودکشی عنوان می نمایند. برخی از مؤلفین برآورد کرده اند که تقریبا ۴۰ درصد افرادی که بطور موفق احیاء شده اند و یا در موقعیتهای تهدید کننده زندگی قرار گرفته اند، تجربه نزدیک مرگ داشته اند. قربانیان اغلب بعضی از وقایع را در طول احیاء بیاد...

متن کامل

Salvarsan – the First Chemotherapeutic Compound

Early History If defined as the use of a specific compound discovered as the result of a systematic search for a cure for a specific disease, then chemotherapy is less than a century old. The first example was the introduction in 1910 by Paul Ehrlich of an organoarsenic compound he named Salvarsan, which provided the first real cure for the extremely unpleasant disease syphilis (caused by the p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: BMJ

سال: 1917

ISSN: 0959-8138,1468-5833

DOI: 10.1136/bmj.1.2923.13-a